Arizona Sen. Martha McSally is introducing a drug pricing bill this week that would allow Medicare to directly negotiate the prices of medicines “that are past their original patent expiration but still maintain a monopoly for that drug.”
McSally’s move is notable as Republicans have traditionally opposed allowing government intervention in drug price negotiations. Only two House Republicans voted for House Democrats’ signature government drug price negotiation bill, H.R. 3 (116), which cleared the lower chamber late last year.
But proponents of government negotiations shouldn’t get too excited just yet. Definitions of “original patent” and “monopoly” will be key to a better understanding of which drugs would be affected by McSally’s plan. Experts see a number of ways in which her plan looks to be weaker than House Democrats plan.
While H.R. 3 permits negotiation on drugs that lack biosimilar or generic competition regardless of whether they are protected by patents or FDA-granted marketing exclusivity, the time at which drug companies have the most leverage to keep prices high, McSally’s plan would have the government intervene at a later point.
Full Content: The Hills
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI